Preimplantation genetic testing (PGT) is an advanced tool in the field of assisted reproduction that can be especially considered in in vitro fertilization (IVF) treatments with double gamete donation. Although the use of donor gametes usually implies a lower risk of genetic disorders, given that donors are generally young and have undergone rigorous health screening, PGT can offer additional benefits.
First, PGT allows embryos to be screened for chromosomal abnormalities prior to transfer to the uterus. This is especially relevant, as even gametes from young, healthy donors are not exempt from the risk of genetic abnormalities. Therefore, PGT can increase the chances of successful treatment, ensuring the transfer of genetically healthy embryos.
Second, in cases where patients have particular medical histories or specific concerns, such as genetic diseases in the family, PGT can be tailored to look for these conditions, although the likelihood of occurrence with selected donors is low.
However, it is important to keep in mind that PGT is not a guarantee of pregnancy and does not eliminate all genetic risks. In addition, the process involves additional steps in IVF treatment, including embryo biopsy and, in some cases, may prolong the time to embryo transfer.
In conclusion, the decision to use PGT in double-donor IVF treatments should be individualized and based on a detailed evaluation of the benefits and risks. It is essential that patients discuss their options with their team of assisted reproduction specialists, who will be able to offer specific advice based on their particular circumstances and treatment goals.
